- Praxis Precision (PRAX): FDA pushed relugtrigine PDUFA from Sep 27 to Dec 27, 2026 after a major amendment. No new trials requested; review stays active as company engages with FDA.
- Needham updated its outlook on Praxis Precision Medicines, raising the firm's price target to $575.00 per share (previously $537.00) while maintaining a Buy rating on PRAX, as reported by the firm.
TradingView
Key facts: Relugtrigine PDUFA moved to Dec 27; Needham ups PRAX PT $575
Praxis Precision (PRAX): FDA pushed relugtrigine PDUFA from Sep 27 to Dec 27, 2026 after a major amendment. No new trials requested; review stays active as company engages with FDA